Shots: The P-III ELEVATE-TN trial involves assessing of Calquence (100 mg bid) as monothx and + obinutuzumab vs chlorambucil + obinutuzumab in 535 patients in ratio (1:1:1) with previously untreated […]readmore
Tags : acalabrutinib
Shots: The P-III ASCEND study involves assessing of Calquence (acalabrutinib, 100mg, q2d) vs Rituximab + Idelalisib/Bendamustine in 310 previously treated patients in a ratio (1:1) with CLL The P-III ASCEND […]readmore